{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["107(1)"],"submitter":["Rossi C"],"pubmed_abstract":["Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate PET metrics could be helpful to identify patients with a high risk of treatment failure with Rituximab. We retrospectively included a total of 132 untreated FL patients separated into training and validation cohorts. Optimal threshold of baseline SUVmax was first determined in the training cohort (n=48) to predict progression-free survival (PFS). The PET results were investigated along with the tumor and immune microenvironment, which were determined by immunochemistry and transcriptome studies involving gene set enrichment analyses and immune cell deconvolution, tog"],"journal":["Haematologica"],"pagination":["221-230"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8719066"],"repository":["biostudies-literature"],"pubmed_title":["Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma."],"pmcid":["PMC8719066"],"pubmed_authors":["Evrard S","Fournie JJ","Robert P","Bories P","Ysebaert L","Franchini DM","Ramla S","Amara N","Martin L","Oberic L","Gravelle P","Bezombes C","Casasnovas RO","Tosolini M","Gilhodes J","Syrykh C","Tabouret-Viaud C","Laurent C","Rossi C","Pericart S","Kanoun S"],"additional_accession":[]},"is_claimable":false,"name":"Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.","description":"Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate PET metrics could be helpful to identify patients with a high risk of treatment failure with Rituximab. We retrospectively included a total of 132 untreated FL patients separated into training and validation cohorts. Optimal threshold of baseline SUVmax was first determined in the training cohort (n=48) to predict progression-free survival (PFS). The PET results were investigated along with the tumor and immune microenvironment, which were determined by immunochemistry and transcriptome studies involving gene set enrichment analyses and immune cell deconvolution, tog","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-06-11T06:01:49.379Z","creation":"2026-06-11T03:12:16.439Z"},"accession":"S-EPMC8719066","cross_references":{"pubmed":["33327711"],"doi":["10.3324/haematol.2020.263194"]}}